Recently, the "2021 Greater China Thoracoscopic Surgery Esophageal Group National Finals" came to an end, and Xie Pengxin, a "post-90s" young attending physician from Shantou Central Hospital's Tumor Surgery Esophageal Cancer Sub-specialty, lasted eight months, through the Shanghai Selection, Provincial and Regional Competitions, and finally won the National Finals Championship. The competition has been held seven times in eight years, and this is the first time that a doctor in Guangdong has won the first place.
It is understood that Xie Pengxin's demonstration of "neoadjuvant immunotherapy for locally advanced esophageal cancer combined with chemotherapy after hypotherapy for thoraco laparoscopic mesophageal resection" has been highly recognized by more than 30 judges in China, Japan, the United States, South Korea and Europe, believing that it fully reflects the standardization and advanced nature of surgical treatment of esophageal cancer. "This competition adopts double-blind anonymous diaspora selection, which has a very high gold content, which fully reflects the leading position of our hospital in the field of esophageal cancer surgery." Fu Junhui, Xie Pengxin's mentor and deputy director of the Oncology Department of Shantou Central Hospital, said that the exchange between the discipline and experts from all over the country will be strengthened to improve the diagnosis and treatment level in the field of esophageal cancer in Shantou.
Fu Junhui and Xie Pengxin undergo laparoscopic esophageal cancer surgery. Courtesy of respondents
Thoracic and abdominal double endoscopy combined with minimally invasive
Surgery for esophageal cancer is performed
The delicate surgical instruments are precisely and steadily excised from the esophageal mesophageal membrane under the operation of the doctor.
The video shows the entire video of Xie Pengxin's surgery. "Esophageal cancer surgery is arguably the most extensive and difficult of thoracic surgery." Fu Junhui said that the combination of thoracoscopic and laparoscopic esophageal cancer surgery has brought great blessings to patients.
Fu Junhui told reporters that esophageal cancer involves the chest and abdomen of the human body, and the wounds of tumor resection surgery in the past are very large, and even one of the patient's ribs needs to be removed first, and then recovered after the resection is completed. The combined operation of "thoracoscopy + laparoscopy" requires only a small wound to carry out resection, which greatly reduces the pain of patients. Less trauma and less bleeding. "The amount of bleeding during the operation is less than a teacup." Fu Junhui said that the precision of minimally invasive disease makes the patient recovery faster, and the operation can speak freely just after the operation, and can be discharged from the hospital in about a week.
On the other hand, the combination of thoracic and abdominal bilocoscopic surgery for esophageal cancer will also make the resection cleaner. "With the help of the instrument, it is possible to probe the tumor in the patient's body from different angles, and it can also have a 10-fold amplification function, so the tumor is removed more thoroughly." Fu Junhui explained. But he also pointed out that for doctors to master thoracoscopic and laparoscopic techniques at the same time, combined surgery, it is not difficult, need to be extremely familiar with minimally invasive anatomy, and be able to standardize all technical details.
Since 2009, when Shantou Central Hospital carried out the first thoracic and abdominal double-laparoscopic combined esophageal surgery in Guangdong Province, the hospital has successfully carried out nearly 3,000 cases of minimally invasive surgery for esophageal cancer. Young physicians such as Li Zhuoyi, Du Zesen, and Xie Pengxin of Fu Junhui's esophageal surgery team have won many awards in the national esophageal cancer surgery competition from 2017 to 2021, representing the level of the hospital's esophageal tumor subspecialty in the field of esophageal surgery.
Introduction of advanced technology
"Clinical + scientific research" to improve the level of medical treatment
Chaoshan people also call esophageal cancer "esophageal cancer", and Chaoshan is an area with a high incidence of esophageal cancer. Fu Junhui casually opened the diagnosis and treatment records of the day, and 30 of the 50 patients who were hospitalized on the same day suffered from esophageal cancer. "Every year, we diagnose and treat 300 to 400 patients with esophageal cancer. Sometimes I see 40 patients in one morning, and there are 20 esophageal cancers. We treat about 300 to 400 patients with esophageal cancer every year. Fu Junhui told reporters.
In order to allow patients to obtain better diagnosis and treatment technology, Shantou Central Hospital continues to explore scientific research innovations and breakthroughs in the field of esophageal surgery. Fu Junhui has presided over a number of national, provincial and municipal scientific research projects, and published more than 100 SCI and national academic papers, of which "Series of Studies on Surgical Treatment of Esophageal Cancer" won the first prize of Shantou Scientific and Technological Achievements in 2009, 2014 and 2015. In 2012, the institute took the lead in carrying out minimally invasive anatomical research on the mesophageal membrane in China, which was approved by the Provincial Science and Technology Department, and the research results were published in national journals and SCI journals.
The introduction of new technologies has made minimally invasive surgery for esophageal cancer more accurate. Xie Pengxin showed reporters a video showing the hospital's first minimally invasive operation for esophageal cancer in China in 2018. Under the label of blue fluorescence, the internal situation of patients with esophageal cancer is clear and intuitive, which facilitates the development of minimally invasive surgery. In 2019, the hospital took the lead in carrying out total mesophageal resection of naked-eye 3D endoscopic esophageal cancer nationwide.
Fu Junhui pointed out that among the patients with esophageal cancer who visit the hospital, most of them are advanced patients, and only 20% to 30% can be directly operated. For patients who cannot undergo surgery immediately, immunotherapy and chemotherapy are needed to shrink the tumor to a degree that can be operated on.
Therefore, in 2018, the hospital took the lead in carrying out a clinical multi-center study of "preoperative immunotherapy combined with chemotherapy for local advanced esophageal cancer" in China, and its results were released at the annual meeting of the American Society of Clinical Oncology in 2021, which was internationally recognized and published in SCI-indexed journals.
Shantou Central Hospital has also carried out a multidisciplinary diagnosis and treatment model for esophageal cancer, and implemented individualized, standardized and multidisciplinary comprehensive diagnosis and treatment of esophageal cancer.
Fu Junhui said that in the future, the cancer surgery department of the hospital will improve the precision and minimally invasive, implement the concept of accelerated rehabilitation, and continuously optimize the surgical process and postoperative rehabilitation measures; establish and improve the multidisciplinary diagnosis and treatment mode of tumors, improve the prognosis of patients, shorten the length of hospitalization; improve the level of clinical scientific research, and benchmark the standard of Shantou Central Hospital as the provincial branch center of the national cancer regional medical center and the provincial sub-center of the national respiratory center, and build the subspecialty into a esophageal surgery department with the characteristics of a central hospital.
[Reporter] Wang Hanqi
【Correspondent】 Huang Qing
Click on the image to report the material with one click
【Author】 Wang Hanqi
【Source】 Southern Press Media Group South + client